EAM Investors’s Corvus Pharmaceuticals CRVS Stock Holding History

EAM Investors’s Portfolio CRVS Stock Details CRVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-138,148	Closed	-$2.02M	–	292
2026 Q1	$2.02M	Buy	+138,148	New	+$2.2M	0.23%	166

Other funds holding CRVS

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

ASP

Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

EAM Investors's CRVS Position: Q2 2026 in Review

EAM Investors sold out of Corvus Pharmaceuticals (CRVS) in Q2 2026, closing a stake of 138,148 shares — an estimated $2.02M sold.

EAM Investors first reported a position in CRVS in Q1 2026 and held it in 1 quarter. The position peaked at $2.02M in Q1 2026. 174 funds tracked by Wall St. Rank hold CRVS as of Q2 2026.

EAM Investors reported no remaining Corvus Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
EAM Investors sold 138,148 Corvus Pharmaceuticals shares in Q2 2026, an estimated $2.02M.
EAM Investors first reported a position in Corvus Pharmaceuticals in Q1 2026 and held it in 1 quarter.
EAM Investors's Corvus Pharmaceuticals position peaked at $2.02M in Q1 2026.
174 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2026.

Based on EAM Investors's 13F filing for Q2 2026, filed 13 Aug 2026.